EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
2023/10/12 by Antonis Fanouriakis, Myrto Kostopoulou, Jeanette Andersen +55 · 42 citations
Medicine · #Systemic Lupus Erythematosus Research #Rheumatoid Arthritis Research and Therapies #Systemic Sclerosis and Related Diseases
paper · pdf · doi:10.1136/ard-2023-224762
Citations
Cited by
- 2026 EULAR updated standardised operating procedures and methods for the development of recommendations or points to consider for the diagnosis and management of people with rheumatic and musculoskeletal diseases
- Impfungen bei Immunsuppression, Immundefekten und immunmodulierenden Therapien: Empfehlungen – Update 2026
- EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update
- A transcriptional patient map of systemic lupus erythematosus reveals disease-related multicellular immune programs conserved between blood and kidney
- Temporal trends in glucocorticoids and hydroxychloroquine for treatment of systemic lupus erythematosus in Sweden
- Lupus nephritis: redefining the treatment goals
- Ten tips in lupus nephritis management
- The role of the patient in rheumatology
- Does Voclosporin Redefine Lupus Nephritis Treatment? A Tri-Focal View of Efficacy, Safety, and Costs
- Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis
- Comorbidity clusters and their relationship with severity and outcomes of index diseases, in a large multicentre systemic lupus erythematosus cohort
- International development and validation of a multilingual bank of items for the self-assessment of essential knowledge by systemic lupus erythematosus patients: the SLE Knowledge Assessment score (SLAKE)
- Achievement of lupus low disease activity state (LLDAS) in a New Zealand cohort: a prospective study of ethnic differences in outcomes
- Patients’ experiences of managing their rare rheumatic disease
- Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee
- Hydroxychloroquine in pregnancy: therapeutic applications, mechanisms of action, and safety — a narrative review
- Prognostic relevance of persistent haematuria in patients with lupus nephritis
- Efficacy of Voclosporin in Proliferative Lupus Nephritis with High Levels of Proteinuria. [europepmc]
- Epigenetic Dysregulation in the Pathogenesis of Systemic Lupus Erythematosus. [europepmc]
- Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort. [europepmc]
- Clinical and laboratory characteristics of early-onset and delayed-onset lupus nephritis patients: A single-center retrospective study. [europepmc]
- Novel and potential future therapeutic options in systemic autoimmune diseases. [europepmc]
- Recommendations for physical activity and exercise in persons living with Systemic Lupus Erythematosus (SLE): consensus by an international task force. [europepmc]
- Defining remission in childhood-onset lupus: PReS-endorsed consensus definitions by an international task force. [europepmc]
- Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations. [europepmc]
- Interferon and B-cell Signatures Inform Precision Medicine in Lupus Nephritis. [europepmc]
- Crosstalk between Inflammation and Atherosclerosis in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Is There a Common Basis? [europepmc]
- Exploring the Link between Varicella-Zoster Virus, Autoimmune Diseases, and the Role of Recombinant Zoster Vaccine. [europepmc]
- Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study. [europepmc]
- Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupus erythematosus. [europepmc]
- Autoimmune diseases refractory to corticosteroids and immunosuppressants. [europepmc]
- "Lupus Myelitis" Revisited: A Retrospective Single-Center Study of Myelitis Associated With Rheumatologic Disease. [europepmc]
- CAR-engineered T cell therapy as an emerging strategy for treating autoimmune diseases. [europepmc]
- Autoimmune disease: a view of epigenetics and therapeutic targeting. [europepmc]
- CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives. [europepmc]
- Advances in Targeted Therapy for Systemic Lupus Erythematosus: Current Treatments and Novel Approaches. [europepmc]
- Hydroxychloroquine: A double‑edged sword (Review). [europepmc]
- Incidence and Factors Associated With Recurrent Pericarditis in Lupus. [europepmc]
- Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics. [europepmc]
- Chronic Inflammatory Diseases and Cardiovascular Risk: Current Insights and Future Strategies for Optimal Management. [europepmc]
- Blood immunophenotyping identifies distinct kidney histopathology and outcomes in patients with lupus nephritis. [europepmc]
- Comprehensive Profiling of Cytokines and Growth Factors: Pathogenic Roles and Clinical Applications in Autoimmune Diseases. [europepmc]